SpringWorks Therapeutics, Inc. financial data

Symbol
SWTX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
100 Washington Boulevard, Stamford, CT
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 20, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 585 % -37.8%
Quick Ratio 11.2 %
Debt-to-equity 15.6 % +2.44%
Return On Assets -41.8 % +26.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 74.9M shares
Common Stock, Shares, Outstanding 74.4M shares +1.25%
Entity Public Float 2.75B USD +71.6%
Common Stock, Value, Issued 7K USD 0%
Weighted Average Number of Shares Outstanding, Basic 74.1M shares +17.4%
Weighted Average Number of Shares Outstanding, Diluted 74.1M shares +17.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 49.3M USD
Research and Development Expense 201M USD +33.2%
General and Administrative Expense 178M USD +47.9%
Costs and Expenses 115M USD +47.9%
Operating Income (Loss) -278M USD +18.9%
Nonoperating Income (Expense) 26M USD +13.3%
Net Income (Loss) Attributable to Parent -258M USD +20.6%
Earnings Per Share, Basic -3.48 USD/shares +32.4%
Earnings Per Share, Diluted -3.48 USD/shares +32.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 69.8M USD -60.4%
Cash, Cash Equivalents, and Short-term Investments 462M USD -30.3%
Accounts Receivable, after Allowance for Credit Loss, Current 46.2M USD +680%
Inventory, Net 10.2M USD +229%
Assets, Current 380M USD -24%
Property, Plant and Equipment, Net 19.7M USD +9.68%
Operating Lease, Right-of-Use Asset 6.98M USD +13.6%
Other Assets, Noncurrent 21.4M USD +44.3%
Assets 587M USD -19.1%
Accounts Payable, Current 12.2M USD +65.6%
Employee-related Liabilities, Current 31.2M USD +19.8%
Accrued Liabilities, Current 86M USD +31.2%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 100M USD +27.9%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 6.18M USD +3.1%
Liabilities 106M USD +6.63%
Accumulated Other Comprehensive Income (Loss), Net of Tax 304K USD -74.5%
Retained Earnings (Accumulated Deficit) -1.15B USD -28.8%
Stockholders' Equity Attributable to Parent 481M USD -23.2%
Liabilities and Equity 587M USD -19.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -78.9M USD -27.7%
Net Cash Provided by (Used in) Financing Activities -552K USD +70.1%
Net Cash Provided by (Used in) Investing Activities 21.5M USD -78.2%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 74.7M shares +1.53%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -58M USD -266%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 70.4M USD -60.2%
Deferred Tax Assets, Valuation Allowance 289M USD +27.3%
Deferred Tax Assets, Gross 293M USD +27.7%
Operating Lease, Liability 7.91M USD +12.1%
Depreciation 253K USD +134%
Payments to Acquire Property, Plant, and Equipment 577K USD -80.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -259M USD +19.8%
Lessee, Operating Lease, Liability, to be Paid 9.07M USD +12.9%
Property, Plant and Equipment, Gross 25.1M USD +21.7%
Operating Lease, Liability, Current 1.73M USD +63.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.27M USD +13.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.25M USD +52.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.15M USD +18.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.18M USD +8.64%
Deferred Tax Assets, Operating Loss Carryforwards 147M USD +21.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.38M USD -27.4%
Additional Paid in Capital 1.65B USD +8.03%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 729K USD +188%
Share-based Payment Arrangement, Expense 109M USD +15.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%